Sustainability of Endovenous Iron Deficiency Anaemia Treatment: Hospital-Based Health Technology Assessment in IBD Patients
Table 2
Intravenous iron formulations available in Italy.
Active ingredient
Ferric gluconate
Ferric carboxymaltose
Iron sucrose
Pharmaceutical form (volume in ml)
po/IV vial (5)
IV vial (10)
IV vial (5)
Amount of elemental iron/vial (mg)
62.5
500
100
Indications
Treatment of iron deficiency anaemia in patients with lack of response to oral iron
Treatment of iron deficiency anaemia in patients with known intolerance or lack of response to oral iron
Iron deficiency: in case of a clinical need for rapid release of iron from reserves: (i) in case of drug intolerance or noncompliant patients; (ii) in case of IBD patients in active phase of disease, when oral iron treatment is not efficient
Maximum dose that can be administered as a single infusion (mg)
From 62.5 to 125
1000
200
Cumulative dose prescribed /patient (based on the most commonly calculated iron needs) (mg)
1000
1000
1000
Time necessary to reach maximum single dose (min)
“Very slowly” (not less than 50)
15 (for a maximum quantity of 1000 mg)
30 (for a maximum quantity of 200 mg)
Number of sessions/visits needed to instil the prescribed dose of 1000 mg (RCP)
16 for a single dosage of 62,5 mg and 8 for a single dosage of 125 mg
1
5
Cumulative time necessary to instil the prescribed dose of 1000 mg (minutes)
(i) 800 when applying “very slowly” (50 per every infusion of 62.5 mg) (ii) 400 for dosage of 125 mg
